Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Breast cancer anxiety's associations with responses to a chemoprevention decision aid.

Dillard AJ, Scherer L, Ubel PA, Smith DM, Zikmund-Fisher BJ, McClure JB, Greene S, Stark A, Fagerlin A.

Soc Sci Med. 2013 Jan;77:13-9. doi: 10.1016/j.socscimed.2012.10.009. Epub 2012 Nov 2.

2.

Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.

Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA.

Breast Cancer Res Treat. 2010 Feb;119(3):613-20. doi: 10.1007/s10549-009-0618-4.

3.

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.

Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA.

Breast Cancer Res Treat. 2011 Jun;127(3):681-8. doi: 10.1007/s10549-011-1450-1. Epub 2011 Mar 26.

4.

Affective forecasting and medication decision making in breast-cancer prevention.

Hoerger M, Scherer LD, Fagerlin A.

Health Psychol. 2016 Jun;35(6):594-603. doi: 10.1037/hea0000324. Epub 2016 Feb 11.

5.

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.

Cancer. 2005 May 15;103(10):1996-2005.

6.

Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.

Korfage IJ, Fuhrel-Forbis A, Ubel PA, Zikmund-Fisher BJ, Greene SM, McClure JB, Smith DM, Alford SH, Fagerlin A.

Breast Cancer Res. 2013;15(5):R74.

7.

Willingness to use tamoxifen to prevent breast cancer among diverse women.

Kaplan CP, Kim SE, Wong ST, Sawaya GF, Walsh JM, PĂ©rez-Stable EJ.

Breast Cancer Res Treat. 2012 May;133(1):357-66. doi: 10.1007/s10549-012-1960-5.

8.

The distinct role of comparative risk perceptions in a breast cancer prevention program.

Dillard AJ, Ubel PA, Smith DM, Zikmund-Fisher BJ, Nair V, Derry HA, Zhang A, Pitsch RK, Alford SH, McClure JB, Fagerlin A.

Ann Behav Med. 2011 Oct;42(2):262-8. doi: 10.1007/s12160-011-9287-8.

9.

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.

Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM.

J Clin Oncol. 2004 Dec 15;22(24):4951-7. Epub 2004 Dec 14.

PMID:
15598980
10.

My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).

Holmberg C, Waters EA, Whitehouse K, Daly M, McCaskill-Stevens W.

Med Decis Making. 2015 Nov;35(8):1010-22. doi: 10.1177/0272989X15594382. Epub 2015 Jul 16.

11.

Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.

Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, Zalles C, Lipkus IM.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1032-4.

12.

"I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.

Paterniti DA, Melnikow J, Nuovo J, Henderson S, DeGregorio M, Kuppermann M, Nease R.

Ethn Dis. 2005 Summer;15(3):365-72.

PMID:
16108294
13.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH.

J Natl Cancer Inst. 2003 Apr 2;95(7):526-32.

PMID:
12671020
14.

Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.

Banegas MP, McClure JB, Barlow WE, Ubel PA, Smith DM, Zikmund-Fisher BJ, Greene SM, Fagerlin A.

Patient Educ Couns. 2013 Jun;91(3):364-71. doi: 10.1016/j.pec.2012.12.014. Epub 2013 Feb 8.

15.

Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.

Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR.

J Clin Oncol. 2002 Jan 1;20(1):9-16.

PMID:
11773148
16.
17.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
18.

Testing whether decision aids introduce cognitive biases: results of a randomized trial.

Ubel PA, Smith DM, Zikmund-Fisher BJ, Derry HA, McClure J, Stark A, Wiese C, Greene S, Jankovic A, Fagerlin A.

Patient Educ Couns. 2010 Aug;80(2):158-63. doi: 10.1016/j.pec.2009.10.021. Epub 2009 Dec 9.

19.
20.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947

Supplemental Content

Support Center